Forbes August 29, 2019
Daniel D'Ambrosio

Alexander Bisignano sold his first company, Recombine, based in New York, for $85 million to CooperSurgical in Pleasanton, California, in 2016, four years after he started it.

Recombine offered a reproductive screening test that lowered the cost for couples to identify the diseases they were at high risk of passing on. It was a $20 million company expected to grow quickly.

Now, for an encore, Bisignano, 31, launched Phosphorus in September 2018, also based in New York at 26thand Broadway, which bills itself as offering “The DNA Test for what matters the most.”

In a good-natured dig at 23andMe and Ancestry.com, Phosphorus encourages its customers to “Go beyond lifestyle and ancestry” and be “proactive” about their health with a genetic...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Patient / Consumer, Precision Medicine, Provider, Technology
Exploring the potential of personalized precision medicine for healthcare industry
Putting Patients First by Extending the Reach of World-Class Care
Healthcare's most promising tech
AI In Healthcare: A New Era Of Personalized Patient Care
23andMe reports sales decline a day after announcing plans to cut 40% of workforce

Share This Article